IL6R and periodontitis: Consistently, treatment of experimental ligature-induced periodontitis by systemic administration of the humanized monoclonal IL-6R antibody tocilizumab suppressed inflammatory cell recruitment, Th17 cytokines and impaired RANKL expression.